Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.
The duration over which antibody responses persist following HPV vaccination is unknown. To estimate the longevity of responses induced by HPV-16 vaccination, two models were fitted to serum anti-HPV-16 levels measured during a 48-month study period. The first was a conventional model of antibody decay and the second was a modified model that accounts for long-lived immune memory. Using the antibody decay model, it was estimated that following administration of a three-dose regimen of HPV-16 vaccine in women aged 16-23 years, anti-HPV-16 levels will remain above those induced naturally by HPV-16 infection for 12 years, and above detectable levels for 32 years in 50% of vaccinees. With the modified model, which fitted the data better (p<0.001), it was estimated that near life-long persistence of anti-HPV-16 following vaccination is expected at titer levels above those associated with reduction of natural HPV-16 infection in 76% of these subjects, and above detectable levels in 99% of these subjects.
Fraser
Christophe
C
Imperial College London, London, UK.
Tomassini
Joanne E
JE
Xi
Liwen
L
Golm
Greg
G
Watson
Michael
M
Giuliano
Anna R
AR
Barr
Eliav
E
Ault
Kevin A
KA
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D052162:Human papillomavirus 16 / Q000276:immunology*; D006801:Humans; D018448:Models, Immunological; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000517:prevention & control*; D022721:Vaccines, Virosome / Q000276:immunology*
D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines; D022721:Vaccines, Virosome